SCHEMBL12370985

SCHEMBL12370985

CS(=O)(=O)c1ncc(-c2ccccc2)c(-c2ccc(C3OCCO3)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 14/20 0.40
PTGS1 P23219 5/20 0.40
ADORA1 P30542 3/20 0.38
ADORA2A P29274 2/20 0.38
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12370988 0.77 ADORA1 (0.38) PTGS2ADORA1ADORA2A
SCHEMBL2274662 0.76 ADORA1 (0.39) ADORA1ADORA2A
SCHEMBL1351892 0.69 AKT1 (0.46)
SCHEMBL1350052 0.69 AKT1 (0.48)
SCHEMBL3597677 0.68 MEN1 (0.48)
SCHEMBL3712735 0.68 AKT1 (0.41) PTGS2PTGS1
SCHEMBL1352411 0.67 CCNB2 (0.39)
SCHEMBL5413235 0.66 BPTF (0.48) PTGS2PTGS1
SCHEMBL6861984 0.66 MAPT (0.43) PTGS2PTGS1
SCHEMBL6016298 0.66 MEN1 (0.47) PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003643-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2011-08-23 US disclosed
US-8003643-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2011-08-23 US disclosed
US-20100075970-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. 2010-03-25 US disclosed
US-20100075970-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. 2010-03-25 US disclosed
US-7655649-B2 Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties MERCK SHARP & DOHME CORP. (US) 2010-02-02 US disclosed
US-7655649-B2 Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties MERCK SHARP & DOHME CORP. (US) 2010-02-02 US disclosed
US-20080280889-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed
US-20080280889-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075970-A1 INHIBITORS OF AKT ACTIVITY PIK3CA, AKT2, AKT1 PTGS2 3413/4885PTGS1 3386/4885ADORA1 2477/4885
US-20080280889-A1 Inhibitors of Akt Activity AKT2, PIK3CA, AKT1 PTGS2 3556/4885PTGS1 3581/4885ADORA1 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.